Recombinant new castle disease LaSota attenuated vaccine strain expressing rabies virus glucoprotein (GP protein)

A technology of rabies virus and attenuated vaccines, which is applied in the field of recombinant virus vaccines and can solve problems such as limitations in the scope of use

Active Publication Date: 2009-03-04
HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after the vaccinia recombinant virus is inoculated into humans, it can inhibit re-immunizat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant new castle disease LaSota attenuated vaccine strain expressing rabies virus glucoprotein (GP protein)
  • Recombinant new castle disease LaSota attenuated vaccine strain expressing rabies virus glucoprotein (GP protein)
  • Recombinant new castle disease LaSota attenuated vaccine strain expressing rabies virus glucoprotein (GP protein)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Construction and biological activity of a recombinant Newcastle disease LaSota attenuated vaccine expressing a gene encoding rabies virus glycoprotein (GP protein)

[0037] 1 Materials and methods

[0038] 1.1 Cells and viruses

[0039] BHK-21 cells (baby hamster kidney cells ATCC CCL-10), Vero-E6 cells (African green monkey kidney cells ATCC No.CRL-1586), the medium is DMEM with 5% fetal bovine serum; rabies virus (RV) ERA strain (AV61) was purchased from the China Institute of Veterinary Drug Control, and the virus titer was titrated on Vero-E6 cells; the recombinant poxvirus vTF7-3 (ATCC, VR-2153) stably expressing T7 polymerase was purchased from ATCC; ERA immunization Mouse serum and chicken anti-NDV hyperimmune serum were purchased from China Veterinary Drug Supervision Institute.

[0040] 1.2 Main reagents and instruments

[0041] FITC-labeled rabbit anti-chicken fluorescent secondary antibody and anti-mouse fluorescent secondary antibody were purchased fro...

Embodiment 2

[0064] Example 2 Immune test of recombinant virus to BALB / c mice

[0065] 1. Materials and methods

[0066] 1.1 Material

[0067] Same as Example 1 above.

[0068] 1.2 Method

[0069] Immune test of recombinant virus to BALB / c mice

[0070] In order to evaluate the immune effect of the recombinant virus on BALB / c mice, the chicken embryos of Example 1 were amplified with allantoxin to 2x10 8 EID 50 Dose Artificial immunization of 6-week-old BALB / c mice (purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) via intraperitoneal injection, and 8 non-immune control groups; the immunized group and the non-immune control group were raised separately In the air negative pressure filter isolator. 21 days after immunization, blood was collected from the heart and the serum was separated according to routine tests for NDV-specific hemagglutination inhibition (HI) antibodies. The virus neutralization test was performed with ERA as the virus antigen to detect anti-ERA a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a Newcastle disease LaSota lentogen vaccine which expresses rabiesvirus glycosidoprotein (GP protein); more specifically, the Newcastle disease LaSota lentogen vaccine is rL-ERAGP. The invention also discloses a method for preparing the Newcastle disease LaSota lentogen vaccine and an application of the Newcastle disease LaSota lentogen vaccine in preparing bivalent vaccine used to prevent rabies and Newcastle diseases.

Description

Technical field [0001] The present invention relates to the field of recombinant virus vaccines. More specifically, the present invention relates to a recombinant Newcastle disease LaSota attenuated vaccine expressing rabies virus glycoprotein (GP protein). More specifically, the recombinant Newcastle disease LaSota attenuated vaccine is rL-ERAGP. The invention also discloses a method for preparing the recombinant Newcastle disease LaSota attenuated vaccine and the application of the recombinant Newcastle disease LaSota attenuated vaccine in preparing a bivalent vaccine for preventing rabies and Newcastle disease. Background technique [0002] Rabies is rabies, also known as hydrophobia, which is an acute viral zoonotic disease that is caused by rabies virus and attacks the central nervous system. Almost all warm-blooded animals are susceptible to rabies virus. Canine animals play a major role in spreading human rabies and are one of the main hosts of this disease. In addition, c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N7/01C12N15/47C12N15/86A61K39/295A61P31/14
Inventor 步志高葛金英
Owner HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap